{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T15:46:05Z","timestamp":1785685565974,"version":"3.56.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["16K10170"],"award-info":[{"award-number":["16K10170"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jid.2018.10.033","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T02:45:19Z","timestamp":1542163519000},"page":"1143-1149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Molecular Basis of Chemical Chaperone Therapy for Oculocutaneous Albinism Type 1A"],"prefix":"10.1016","volume":"139","author":[{"given":"Ayako","family":"Teramae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kunimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Tsuruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Fukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2018.10.033_bib1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.0906-6705.2005.00337.x","article-title":"DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in\u00a0vivo skin lightening potency","volume":"14","author":"Boissy","year":"2005","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2018.10.033_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1034\/j.1600-0749.2001.140203.x","article-title":"The mouse p (pink-eyed dilution) and human P genes, oculocutaneous albinism type 2 (OCA2), and melanosomal pH","volume":"14","author":"Brilliant","year":"2001","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.jid.2018.10.033_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0378-1119(94)90114-7","article-title":"Sequence of the human dopachrome tautomerase-encoding TRP-2 cDNA","volume":"143","author":"Cassady","year":"1994","journal-title":"Gene"},{"key":"10.1016\/j.jid.2018.10.033_bib4","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.3390\/ijms10062440","article-title":"An updated review of tyrosinase inhibitors","volume":"10","author":"Chang","year":"2009","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2018.10.033_bib5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/j.1365-2133.2008.08864.x","article-title":"Mechanism of tyrosinase inhibition by deoxyArbutin and its second-generation derivatives","volume":"159","author":"Chawla","year":"2008","journal-title":"Br J Dermatol"},{"issue":"1\u20132","key":"10.1016\/j.jid.2018.10.033_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0167-4838(00)00230-2","article-title":"Effect of captopril on mushroom tyrosinase activity in\u00a0vitro","volume":"1544","author":"Espin","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jid.2018.10.033_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2018.10.033_bib8","doi-asserted-by":"crossref","first-page":"25607","DOI":"10.1074\/jbc.M303411200","article-title":"Tyrosinase maturation and oligomerization in the endoplasmic reticulum require a melanocyte-specific factor","volume":"278","author":"Francis","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jid.2018.10.033_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jdermsci.2004.06.007","article-title":"Tyrosinase gene analysis in Japanese patients with oculocutaneous albinism","volume":"35","author":"Goto","year":"2004","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2018.10.033_bib10","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1073\/pnas.97.11.5889","article-title":"Endoplasmic reticulum retention is a common defect associated with tyrosinase-negative albinism","volume":"97","author":"Halaban","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2018.10.033_bib11","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/humu.21516","article-title":"Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in \u03b2-galactosidase deficiency","volume":"32","author":"Higaki","year":"2011","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jid.2018.10.033_bib12","first-page":"19","article-title":"Non-random distribution of missense mutations within the human tyrosinase gene in type I (tyrosinase-related) oculocutaneous albinism","volume":"8","author":"King","year":"1991","journal-title":"Mol Biol Med"},{"key":"10.1016\/j.jid.2018.10.033_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.bbadis.2007.02.003","article-title":"Enzyme enhancement activity of N-octyl-\u03b2-valienamine on \u03b2-glucosidase mutants associated with Gaucher disease","volume":"1772","author":"Lei","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jid.2018.10.033_bib14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0021-9258(18)56226-8","article-title":"Mammalian tyrosinase; the relationship of copper to enzymatic activity","volume":"187","author":"Lerner","year":"1950","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jid.2018.10.033_bib15","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","article-title":"Chemical chaperone therapy for brain pathology in GM1-gangliosidosis","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2018.10.033_bib16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000018218","article-title":"A\u00a0splicing mutation of the tyrosinase gene causes yellow oculocutaneous albinism in a Japanese patient with a pigmented phenotype","volume":"199","author":"Matsunaga","year":"1999","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2018.10.033_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.0022-202X.2005.23815.x","article-title":"Five novel mutations in tyrosinase gene of Japanese and Indian patients with oculocutaneous albinism type I (OCA1)","volume":"125","author":"Miyamura","year":"2005","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2018.10.033_bib18","doi-asserted-by":"crossref","first-page":"8150","DOI":"10.1128\/JVI.72.10.8150-8157.1998","article-title":"Development of a self-inactivating lentivirus vector","volume":"72","author":"Miyoshi","year":"1998","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jid.2018.10.033_bib19","doi-asserted-by":"crossref","first-page":"10319","DOI":"10.1073\/pnas.94.19.10319","article-title":"Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector","volume":"94","author":"Miyoshi","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2018.10.033_bib28","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1248\/bpb.27.806","article-title":"Inhibition effect of miconazole on melanogenesis","volume":"27","author":"Mun","year":"2004","journal-title":"Bio Pharm Bull"},{"key":"10.1016\/j.jid.2018.10.033_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jdermsci.2013.12.011","article-title":"Oculocutaneous albinism (OCA) in Japanese patients: five novel mutations","volume":"74","author":"Okamura","year":"2014","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2018.10.033_bib21","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S \u03b2-glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2018.10.033_bib22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/1523-1747.ep12319351","article-title":"Mutational analysis of copper binding by human tyrosinase","volume":"109","author":"Spritz","year":"1997","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2018.10.033_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4137\/PMC.S2332","article-title":"Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities","volume":"3","author":"Suzuki","year":"2009","journal-title":"Perspect Medicin Chem"},{"key":"10.1016\/j.jid.2018.10.033_bib24","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1096\/fj.01-0216com","article-title":"Oculocutaneous albinism types 1 and 3 are ER retention diseases: mutation of tyrosinase or Tyrp1 can affect the processing of both mutant and wild-type proteins","volume":"15","author":"Toyofuku","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.jid.2018.10.033_bib25","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/ajmg.1320430523","article-title":"Tyrosinase gene mutations in type I (tyrosinase-deficient) oculocutaneous albinism define two clusters of missense substitutions","volume":"43","author":"Tripathi","year":"1992","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.jid.2018.10.033_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0749.2005.00288.x","article-title":"Tyrosinase maturation through the mammalian secretory pathway: bringing color to life","volume":"19","author":"Wang","year":"2006","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.jid.2018.10.033_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1432-1033.1991.tb16018.x","article-title":"New assays for the tyrosine hydroxylase and dopa oxidase activities of tyrosinase","volume":"198","author":"Winder","year":"1991","journal-title":"Eur J Biochem"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X18328112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X18328112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:12:06Z","timestamp":1758301926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X18328112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0022202X18328112"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2018.10.033","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Molecular Basis of Chemical Chaperone Therapy for Oculocutaneous Albinism Type 1A","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2018.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}